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Abstract
Objectives: The aim of this study was to evaluate the chronic effects of mesoglycan on the vascular 
remodeling in patients with metabolic syndrome (Mets).
Background: MetS is defined by a clustering of vascular risk factors that require both pharmacologic 
and non-pharmacologic interventions, including body weight reductions and physical activity. The 
correction of vascular remodeling associated with MetS has lately received increasing interest.
Methods: Thirty consecutive ambulatory patients affected by MetS were 2:1 randomized in a double-
blind fashion to receive mesoglycan or placebo, respectively. At the beginning and after 90 days of 
oral treatment we appraised the effects of mesoglycan (50 mg per os bid) or placebo on vascular 
remodeling, as assessed by the measurement of arterial wall elastic properties. Moreover, the matrix 
metalloproteinase’s (MMPs) type 9 and tissue inhibitor of metalloproteinase (TIMP) type 1 were 
analyzed by enzyme-linked immune sorbent assay (ELISA) and gelatin substrate zymography at the 
beginning of the study and after 90 days of treatment.
Results: After 90 days of treatment, a marked improvement of arterial distensibility and compliance 
was detected in Mesoglycan group, with associated significant reduction of arterial stiffness, and a 
significant reduction of serum levels of MMP-9 and TIMP-1 and significant reduction of enzyme 
activity of MMPs.
Conclusions: This small, preliminary study shows that mesoglycan exerts relevant effects on 
vascular remodeling after three-month treatment, in patients affected by metabolic syndrome. 
Keywords: Mesoglycan; Arterial stiffness; Coefficient of distensibility; Matrix metallo 
proteinases; Metabolic syndrome
Introduction
Metabolic syndrome (MetS) is defined by a clustering of risk factors, including hypertension, 
dyslipidaemia, excess body weight, and altered glucose homeostasis, which leads to increased risk 
for cardiovascular disease (CVD) [1]. Insulin Resistance (IR) could be the common pathogenic 
pathway of these risk factors [2,3], whereas appropriate life style changes represent the gold 
standard treatment for MetS. However, body weight reduction and physical activity programs 
[4-6] together to the control of blood pressure values and altered glucose and/or lipid profiles 
could not be sufficient to achieve an adequate management of MetS patients, determining the 
necessity of pharmacological treatments [1]. In this regard endothelial dysfunction, as well as pro-
inflammatory and pro-thrombotic states [7-10], could represent an interesting pharmacological 
target. Mesoglycan is a glycosaminogly can compound extracted from porcine intestinal mucosa 
and composed of heparan sulphate (48%), derma tan sulphate (36%), and electro phoretically slow-
moving heparin (8%), and chondroitin sulphate (8%). Heparan and dermatan sulphate are thrombin 
inhibitors that act through complementary pathways [11,12], heparan sulphate also inhibits factor 
Xa [11]. Mesoglycan exerts several effects on the antithrombotic and profibrinolitic pathways and, 
according to some clinical studies, could also be useful in patients with cerebral vascular disease 
[13,14]. Moreover, mesoglycan treatment reduces thrombophlebitis recurrences in patients with 
previous deep vein thrombosis [15], and increases the free-pain walking distance in non diabetic 
patients affected with peripheral artery disease [16]. The complete effects of mesoglycan on the 
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mechanisms of the vascular remodeling have not yet completely 
recognized, even if it has well been documented that endothelial 
cells bind and internalize exogenous sulphated polysaccharides, such 
as heparin and heparan sulphate [17,18], and are able to generate 
endogenous heparan sulphate [19]. In a previous study, we observed 
that acute and chronic treatment with mesoglycan improved the 
vascular reactivity in patients affected with Metabolic Syndrome [20]. 
Moreover, we also observed a worsened arterial elasticity in MetS 
patients in respect to healthy control subjects at the beginning, as 
observed in other patients at high cardiovascular risk, particularly in 
hypertensive’s [20-24]. It has been also reported a possible landmark 
role of the endopeptidates MMPs in the development of higher 
vascular stiffness in hypertensive and diabetic patients [25-27], which 
has been associated with an increase of cardiovascular morbidity and 
mortality in these patients [28-31]. According to our previous report 
[20], the aim of this study was to evaluate the long-term effects of 
mesoglycan on arterial stiffness through the impact of the substance 
on MMP/TIMP system in a group of MetS patients.
Population, Materials and Methods
Thirty consecutive ambulatory patients affected by MetS and 
recruited from the Department of Translational Medical Sciences of 
the University Federico II of Naples were enrolled in a clinical trial 
between May 2013 and June 2014. MetS was defined according to 
the American Heart Association criteria [1] based on the presence 
of any 3 of the following 5 abnormalities: abdominal obesity, hyper 
triglyceridemia, high Blood Pressure (BP), low High-Density 
Lipoprotein Cholesterol (HDL-C), and elevated fasting glucose. The 
exclusion criteria were the presence of a critical illness (i.e., heart 
failure, severe valve heart disease, and neoplasms, advanced renal 
or liver disease), history of vascular disease or adverse side effects 
of mesoglycan and heparinoids, bleeding, pregnancy, surgery in the 
previous three months, and insulin treatment. At the beginning of 
the trial patients were double-blindly randomized into two arms, 
according to a 2:1 scheme: one group (20 patients) received oral 
tablets of mesoglycan 50 mg twice a day (mesoglycan group) and 
the other (10 patients) received placebo (placebo group). We opted 
for this randomization scheme because it offered the advantage of 
increasing the statistical power for paired comparisons of the treated 
group (baseline vs. after treatment). Mesoglycan, 50 mg capsules, and 
matching placebos (capsules containing excipients only, respectively) 
were provided by Mediolanum Farmaceutici, Milan, Italy. At 
baseline and at the end of the 90-day period, all patients underwent 
an ultrasound evaluation to assess the elastic arterial wall properties, 
using standard parameters, such as Distensibility Coefficient 
(DC), brachial artery Compliance Coefficient (CC), brachial artery 
stiffness (β), Gosling index (pulsatility index, PI), and Pourcelot 
index (Resistive Index, RI). Moreover, all patients underwent a 
laboratory evaluation at the basal visit and after 90 days, including 
the measurements of metalloproteasis MMP-9 and specific tissue 
inhibitor TIMP-1 by ELISA and as gelatin substrate zymography. 
Thirty well matched healthy subjects were also recruited and served 
as a control group for comparison with the MetS group at baseline. 
These subjects were studied only at baseline and did not receive any 
treatment. All participants gave their informed written consent. The 
protocol was approved by the Ethics Committee of the University 
Federico II and registered at ClinicalTrial.gov with # NCT02254850.
MMP-9 and TIMP-1
Peripheral venous blood samples were collected from all 
individuals. Native serum was prepared using plastic tubes without 
coagulation accelerators, to prevent the release of gelatinases during 
platelet activation. Tubes were centrifuged at 1600 g for 10 min, 30 
min after blood collection. For each sample, determination of 
protein concentration was performed using the method of Bradford 
[32]. Sera were aliquoted and stored at -20ºC until used. Each aliquot 
was used only once in order to prevent enzyme activation due to 
freeze- thawing processes.
ELISA assay of MMP-9 and TIMP-1 
MMP-9 and TIMP-1 levels were detected by quantitative 
sandwich ELISA using commercial kits obtained from R&D Systems 
(Minneapolis, MN, USA). These assays are based on a two-site 
sandwich format using two antibodies directed against various 
epitopes of the molecule. All analyses were performed according 
to the manufacturer’s instructions. Gelatin substrate zymography. 
Gelatinolytic activity was performed as previously described and, 
Figure 1: MMP-9 and TIMP-1 values in Mesoglycan Groups 
at baseline (Time 0) and after 90 days (Time 90) of treatment. 
Data are expressed as mean ± Standard Deviation and compared with 
Wilcoxon signed Rank test.
Figure 2: MMP-9 92 kDa (A) and MMP-9 kDa (B) values in Mesoglycan 
Groups at baseline (Time 0) and after 90 days (Time 90) of treatment.
Data are expressed as mean ± Standard Deviation and compared with 
Wilcoxon signed Rank test
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following zymography, the degree of gelatin digestion was quantified. 
We used image analysis software (Image Quant TL, Amersham 
Bioscience, and Chicago, IL, USA): the image of the gel was inverted 
revealing dark bands on a white background. The molecular weight, 
volume and background of each band were determined. The relative 
amounts of the different forms of both serum and urine gelatinizes 
were expressed as the integrated density x 10-3 (volume) of all the 
pixels above the background of each band.
Brachial artery elastic properties
All subjects performed the evaluation of brachial artery elastic 
properties at baseline and at the end of the 90 days treatment. They 
were evaluated in a quiet, temperature-controlled room (22ºC) after 
12 h of fasting, including caffeine, and abstaining from cigarette 
smoking and drugs from the day before the examination. Tests were 
performed at the same time of day for each patient (approximately 
12:00). An ultrasound system equipped with a multi-frequency 
transducer with a minimum frequency of 7.5 MHz was used (Aplio 
XG Imaging System, Toshiba, Japan). The parameters measured 
were: diastolic arterial diameter, Dd (mm); variation in arterial 
diameter over time, ΔD (mm); thickness of the arterial wall, IMTb 
(mm); variation in arterial pressure, ΔP (kPa). Arterial distensibility, 
compliance, and stiffness, were then derived using the following 
equations:
DC= (2ΔD*Dd+ ΔD2)/ ΔP*Dd2
CC= π (2Dd* ΔD + ΔD2)/4 ΔP
β= ln(SBP/DBP)/(ΔD/Dd)
Where ln is the natural logarithm and SBP and DBP are the 
brachial systolic and diastolic pressures, respectively [34-36]. We also 
evaluated Pourcelot Index and Gosling Index, which represent partial 
quantitative parameters of blood flow as assessed by the ratio between 
the difference of the brachial artery maximum systolic velocity (Vs) 
and diastolic velocity (Vd) to the maximum systolic velocity (Resistive 
Figure 3:  Gelatin zymography examples in patient treated with Mesoglycan 
(A) or Placebo (B) at baseline and after 90 days of treatment.
Figure 4: Regression analysis in Mesoglican Group at baseline (A) and after 
90 days of treatment and correlation with Coefficient of Distensibility (DC).
Figure 5: Regression analysis in Mesoglican Group at baseline (A) and after 
90 days of treatment and correlation with Beta Stiffness.
MetS 
(n=30)
Controls 
(n=30) p 
Ϯ,*
Age (years) 52.5 ± 8.9 53.7 ± 6.9 0.95 Ϯ
Sex (n) 12F/18M 13F/17M 0.79*
SBP (mmHg) 132.4 ± 12.7 124.3 ± 10.5 <0.01Ϯ
DBP (mmHg) 84.5 ± 10.0 80.2 ± 8.6 0.07Ϯ
Waist Circumference (cm) 99.3 ± 6.3 92.5 ± 8.5 <0.01Ϯ
Total Cholesterol (mg/dL) 205.9 ± 33.9 188.7 ± 22.9 0.06Ϯ
HDL-C (mg/dL) 43.3 ± 9.1 43.3 ± 9.1 0.03Ϯ
LDL-C (mg/dL) 130.7 ± 49.4 111.9 ± 14.4 0.05Ϯ
Triglyceridemia (mg/dL) 181.1 ± 81.7 133.7 ± 32.2 <0.01Ϯ
Fasting Glycaemia (mg/dL) 96.1 ± 17.2 93.2 ± 11.8 0.66Ϯ
HbA1c (%) 5.76 ± 0.72 5.44 ± 0.26 0.02Ϯ
Fasting Insulin (μU/ml) 19.3 ± 7.1 14.1 ± 3.3 <0.01Ϯ
HOMA Index 2.49 ± 0.9 1.83 ± 0.5 <0.01Ϯ
Fibrinogen (mg/dL) 346.22±58.75 307.4±26.11 <0.01 Ϯ
Protein C (%) 120.68±14.30 127.3±12.5 0.05Ϯ
Protein S (%) 100.7±9.96 102.5±9.9 0.46Ϯ
Antithrombin III (%) 104.64±7.28 109.4±8.5 0.04Ϯ
Smokers (n) 17/30 19/30 0.79*
Table 1: Anthropometric and laboratory parameters in patients with the metabolic 
syndrome (MetS) and healthy control subjects at baseline.
Data are expressed as mean ± standard deviation or frequencies when indicated.
*: χ2 test with Yate’s correction. Ϯ: Mann-Whitney U test. MetS: Metabolic 
Syndrome; SBP: Systolic Blood Pressure;DBP: Diastolic Blood Pressure; 
HDL-C: High Density Lipoprotein – Cholesterol; LDL-C: Low Density Lipoprotein 
– Cholesterol; HbA1c: Haemoglobin A1c.
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Index, RI) or to the time-averaged velocity (Pulsatility Index, PI) 
[37]. The coefficient of variation for the arterial DC in our laboratory 
was 5%. To guarantee blinding, three operators were involved: one 
measured the distensibility parameters in all patients and was blinded 
to the treatment assigned, another operator performed the offline 
readings of the vascular exams and was blinded both to the treatment 
assigned and time of examination, one additional operator assigned 
to the patients a code number corresponding to mesoglycan or 
placebo, in undistinguishable packaging.
Statistical analysis
Data are presented as the means ± standard deviation. Statistical 
significance between groups was tested by the Mann-Witney U test 
for independent samples, Wilcox on test for paired samples, and 
chi-square test with Yates correction for non-continuous variables. 
Spearman’s rank correlation test and stepwise regression analysis 
were performed. A p value less than 0.05 was considered statistically 
significant. All calculations were performed with the SPSS software, 
version 13 (SPSS Inc., Chicago IL).
Results
Table 1 shows the clinical and laboratory characteristics of 
the MetS patients compared with a control group of matched 
 MetS (n=30) Controls (n=30) pϮ
DC (10-3/kPa) 2.38 ± 1.14 3.03 ± 1.12 0.03
CC (mm2/kPa) 7.49 ± 3.57 9.51 ± 3.52 0.04
β 10.11 ± 3.95 6.51 ± 3.16 <0.01
PI 7.21 ± 2.42 5.42 ± 2.18 <0.01
RI 0.92 ± 0.02 0.88 ± 0.06 <0.01
Table 2: Elastic properties in MetS patients and healthy control subjects at base-
line.
Data are .expressed as mean ± standard deviation
Ϯ: Mann-Whitney U test MetS: Metabolic Syndrome; FMD: Flow Mediated 
Dilation; DC: Coefficient of Distensibility; CC: Compliance Coefficient; β: Beta 
Stiffness; PI: Pulsatility Index; RI: Resistive Index.
 Base line  After 90 days  
 Mesoglycan Placebo p†,* Mesoglycan Placebo p†,*
Age (years) 52.9 ± 9.6 51.3 ± 7.4 0.45 † 52.9 ± 9.6 51.3 ± 7.4 0.45 †
Sex (n) 7F/13M 5F/5M 0.69* 7F/13M 5F/5M 0.69*
SBP (mmHg) 134 ± 13.1 131 ± 12.9 0.70† 134 ± 8.4 131 ± 9.1 0.47†
DBP (mmHg) 85.2 ± 13.1 84.5 ± 11.2 0.88† 80.2 ± 8.7 85 ± 4.7 0.14†
Waist Circumference (cm) 97.9 ± 5.8 98.3 ± 5.6 0.61† 97.4 ± 5.5 98.7 ± 4.9 0.45 †
Total Cholesterol (mg/dL) 204.2 ± 34.1 208.1 ± 36.2 0.57† 199.1 ± 46. 194.9 ± 19.9 0.36†
HDL-C (mg/dL) 43.5 ± 8.9 42.9 ± 10.1 0.83† 45.8 ± 9.8 41.8 ± 8.6 0.25†
LDL-C (mg/dL) 134.6 ± 59.1 122.9 ± 18.9 0.79† 120 ± 38.2 121 ± 30.3 0.61†
Triglyceridemia (mg/dL) 173.7 ± 68.6 196 ± 108.2 0.71† 167.2 ± 94.7 191.7 ± 32.9 0.06†
Fasting Glycaemia (mg/dL) 100.7 ± 22.9 95.3 ± 13.3 0.34† 84.8 ± 9.9 97.4 ± 10.9 <0.01†
HbA1c (%) 5.73 ± 0.62 5.82 ± 0.94 0.84† 5.44 ± 0.72 5.9 ± 0.75 0 .15†
Fasting Insulin (μU/ml) 19.57 ± 7.15 19.19 ± 7.24 0.68† 14.3 ± 5.98 19.32 ± 6.27 0.01†
HOMA Index 2.54 ± 0.92 2.45 ± 0.92 0.66† 1.81 ± 0.77 2.51 ± 0.79 <0.01†
Fibrinogen(mg/dL) 343.76 ± 48.96 351.13 ± 77.58 0.93† 315.51 ± 56.92 362.01 ± 46.65 0.04†
Protein C (%) 120.60 ± 14.17 120.83 ± 15.32 0.95† 129.09 ± 13.93 119.28 ± 7.38 0.03†
Protein S (%) 98.9 ± 10.41 104.3 ± 8.34 0.12† 110.85 ± 11.67 102.2 ± 5.79 0.05†
Antithrombin III (%) 105.53 ± 7.73 102.88 ± 6.29 0.42† 111.62 ± 8.35 101.89 ± 3.96 0.02†
Smokers (n) 13/20 4/10 0.36* 13/20 4/10 0.36*
Hypertension Treatment (n): 
ACEInhibitors(Ramipril)
Ca2+channelblockers(Amlodipine) 
β-blockers(Bisoprolol,Nebivolol) 
Diuretics (Indapamide)
7/20 
(3)  
(2)  
(1)  
(1)
5/10 
(2) 
(1) 
(2) 
-
7/20 
(3) 
(2) 
(1) 
(1)
5/10 
(2) 
(1) 
(2) 
-
Diabetes Oral Treatment (n): 
Glibencamide 
Metformin
3/20 
(1)  
(2)
1/10 
 
(1)
3/20 
(1) 
(2)
1/10 
 
(1)
 
Dislipidemia Treatment(n): 
 
Statins 
 
Ezetimibe 
 
Omega3 
 
Fibrates
3/20 
 
(1) 
 
 - 
  
 - 
  
(2)
2/10
 
- 
 
(1) 
 
(1) 
 
-
3/20 
 
(1) 
 
- 
 
- 
 
(2)
2/10 
 
- 
 
(1) 
 
(1) 
 
-
 
Table 3: Anthropometric and laboratory parameters in Mesoglycan and Placebo groups at baseline and after 90 days.
Data are expressed as mean ± standard deviation or frequencies when indicated.
*: χ2 test with Yate’s correction; †:Mann-Whitney U test. SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HDL-C: High
Density Lipoprotein - Cholesterol; LDL-C: Low Density Lipoprotein - Cholesterol; HbA1c: Haemoglobin A1c
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healthy subjects. The parameters adopted as inclusion criteria for 
MetS were, as expected, significantly different from the controls. 
Fasting glucose was only slightly higher in MetS patients, while 
HbA1c resulted significantly different pointing to abnormal gluco 
regulation, as reported in our previous study [20]. As summarized 
in (Table 2), the MetS patients showed marked alterations in the 
basal parameters of elastic properties in respect to healthy control 
subjects, in particular the indices of arterial performance showed 
concordant abnormalities of distensibility, compliance, and stiffness. 
Table 3 shows the clinical and laboratory characteristics of the 
patients after they were randomized into the two groups, receiving 
either mesoglycan or placebo. There were no differences in any of the 
parameters considered. As shown in the Table, some of the patients 
were under pharmacologic treatment for hypertension, diabetes, or 
dyslipidaemia. No changes in the pharmacological treatments were 
made throughout the study period. After 90 days of treatment with 
mesoglycan, the serum levels of MM9 and TIMP, as well as MMP-
9 activity at 92 kDa and 240 kDa, significantly decreased (Figure 
1.2 A,B). Gelatin zymography examples in patient treated with 
Mesoglycan or Placebo at baseline and after 90 days of treatment 
 MESOGLYCAN PLACEBO   
 Baseline After 90 Days p# Baseline After 90 Days p#
SBP(mmHg) 134 ± 13.1 134 ± 8.4 0.88 131 ± 12.9 131 ± 9.1 0.95
DBP(mmHg) 85.2 ± 13.1 80.2 ± 8.7 0.05 84.5 ± 11.2 85 ± 4.7 0.94
WC(cm) 97.9 ± 5.8 97.4 ± 5.5 0.39 98.3 ± 5.6 98.7 ± 4.9 0.68
Total Cholesterol(mg/dL) 204.2 ± 34.1 199.1 ± 46.2 0.76 208.1 ± 36.2 194.9 ± 19.9 0.24
HDL-C(mg/dL) 43.5 ± 8.9 45.8 ± 9.8 0.29 42.9 ± 10.1 41.8 ± 8.6 0.63
LDL-C(mg/dL) 134.6 ± 59.1 120 ± 38.2 0.7 122.9 ± 18.9 121 ± 30.3 0.86
Triglyceridemia(mg/dL) 173.7 ± 68.6 167.2 ± 94.7 0.75 196 ± 108.2 191.7 ± 32.9 0.84
Fasting Glycaemia(mg/dL) 100.7 ± 22.9 84.8 ± 9.9 0.03 95.3 ± 13.3 97.4 ± 10.9 0.88
HbA1c(%) 5.73 ± 0.62 5.44 ± 0.72 0.08 5.82 ± 0.94 5.9 ± 0.75 0.51
Fasting Insulin(μU/ml) 19.57 ± 7.15 14.3 ± 5.98 0.04 19.19 ± 7.24 19.32 ± 6.27 0.17
HOMA Index 2.54 ± 0.92 1.81 ± 0.77 0.05 2.45 ± 0.92 2.51 ± 0.79 0.21
Fibrinogen(mg/dL) 343.76±48.96 315.51±56.92 0.04 351.13±77.58 362.01±46.65 0.72
Protein C(%) 120.60±14.17 129.09±13.94 0.02 120.83±15.32 119.28±7.38 0.72
Protein S(%) 98.9±10.41 110.85±11.67 <0.01 104.3±8.34 102.2±5.79 0.33
Antithrombin III(%) 105.53±7.73 111.62±8.35 0.04 102.88±6.3 101.89±3.96 0.58
MMP-2 (72 kDa)Volume x 10-3 428.37± 176.08 475.28±210.15 0.28 421.99±283.34 496.90±246.20 0.56
MMP-9 (92 kDa)Volume x 10-3 940.15 ± 436.12 653.41± 271.22 0.042 1093.23 ± 578.47 949.97 ± 528.14 0.57
MMP-9 (240 kDa)Volume x 10-3 91.50 ± 57.39 62.87 ± 17.91 0.046 98.11 ± 52.88 82.07 ± 35.72 0.51
MMP-9 (ng/ml) 441.23 ± 248.32 315.98 ± 101.79 0.035 537.90 ± 183.52 437.20 ± 120.22 0.49
TIMP-1 (ng/ml) 277.34 ± 154.63 209.48 ± 105.98 0.049 195.80 ± 113.19 189.72 ± 110.76 0.73
DC(10-3/kPa) 2.25 ± 0.93 4.54 ± 1.64 <0.01 2.65 ± 1.49 2.60 ± 1.25 0.88
CC(mm2/kPa) 7.07 ± 2.92 14.30 ± 5.17 <0.01 8.33 ± 4.69 8.19 ± 3.94 0.88
β 10.45 ± 4.01 5.83 ± 1.79 <0.01 9.45 ± 3.96 8.7 ± 5.61 0.58
RI 0.96 ± 0.02 0.88 ± 0.08 <0.01 0.95 ± 0.02 0.94 ± 0.03 0.51
PI 7.20 ± 2.7 5.22 ± 1.86 0.02 7.19 ± 1.6 6.85 ± 1.84 0.87
Table 4: Anthropometric, laboratory and vascular parameters in Mesoglycan and Placebo groups at baseline and after 90 days.
Data are expressed as mean ± standard deviation when indicated. #:Wilcoxon signed-rank test. SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HDL-C: 
High Density Lipoprotein - Cholesterol; LDL-C: Low Density Lipoprotein  - Cholesterol;  HbA1c:  Haemoglobin  A1c;  MMP-9:  Matrix Metalloproteinase  type 9; TIMP-
1: tissue inhibitor of Metallo Proteinase type 1; DC: coefficient of distensibility;C: Compliance Coefficient; β: Beta Stiffness; RI: Resistive Index; PI: Pulsatility Index.
 DC (10-3/kPa)
CC 
(mm2/kPa) β PI RI
Mesoglycan (Baseline) 2.25 ± 0.93 7.07 ± 2.92 10.45 ± 4.01 7.20 ± 2.7 0.96 ± 0.02
Placebo (Baseline) 2.65 ± 1.49 8.33 ± 4.69 9.45 ± 3.96 7.19 ± 1.6 0.95 ± 0.02
p † 0.6 0.6 0.48 0.54 0.93
Mesoglycan (after 90 days) 4.54 ± 1.64 14.30 ± 5.17 5.83 ± 1.79 5.22 ± 1.86 0.88 ± 0.08
Placebo (after 90 days) 2.60 ± 1.25 8.19 ± 3.94 8.7 ± 5.61 6.85 ± 1.84 0.94 ± 0.03
p † <0.01 <0.01 0.05 0.02 <0.01
Table 5: Brachial artery elastic properties in Mesoglycan and Placebo groups at baseline and after 90 days.
Data are expressed as mean ± Standard Deviation.
†:Mann-Whitney U test. DC: coefficient of distensibility; CC: Compliance Coefficient; β: Beta Stiffness;
PI: Pulsatility Index; RI: Resistive Index
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are showed in (Figure 3 A,B). Fasting glucose and HbA1c were also 
significantly reduced by mesoglycan, indicating an improvement of 
glucoregulation in treated patients. Protein C, Protein S, and ATIII 
activities increased after mesoglycan treatment, whereas fibrinogen, 
but also MMP-9 and TIMP-1, both quantitatively and qualitatively 
decreased (Table 4). None of the arterial elastic properties measured 
were different between the mesoglycan and placebo groups at 
baseline. Moreover, after 90 days of treatment, in the mesoglycan 
group there was a marked improvement in arterial elasticity, as 
documented by increased distensibility and compliance, reduced 
stiffness, and improvements in both pulsatile and resistive indices 
(Table 5). The data were also analyzed by stepwise multiple regression 
to determine which factor was predictive of vascular improvement. 
In this analysis, β-stiffness and Coefficient of Distensibility (DC) 
were the dependent variables whereas glycaemia, HbA1c, SBP, DBP, 
total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, 
MM9 and TIMP1 were used as independent variables. The results 
indicate a significant predictive value for the MMP-9 240kDa values 
(standardized β= -0.07, p=0.005 for Beta stiffness and standardized 
β= 0.05, p=0.03 for DC, respectively) as summarized in (Figure 4A,B) 
and (Figure 5A,B). All patients completed the chronic treatment with 
mesoglycan without reporting major side effects. Four patients in the 
mesoglycan group and two patients in the placebo group experienced 
mild dyspepsia.
Discussion
Recent studies have suggested a beneficial effect of mesoglycan 
in patients affected by peripheral arterial disease [16-38] or deep vein 
thrombosis [15]. MetS is associated with marked abnormalities of 
arterial vascular function [39,40], and can represent a useful model 
to test the hypothesis that an adequate treatment could be effective 
in improving vascular remodeling in patients at high cardiovascular 
risk. For this reason this small, exploratory trial, aimed to explore the 
potential effects of mesoglycan on the elastic vessel properties, was 
exactly conducted in MetS patients. The results are considerable: the 
current study demonstrates that mesoglycan exerts relevant effects 
on vascular physiology after a prolonged, three-month period of 
treatment. The effects of mesoglycan were significant at the level 
of the whole vascular function, as documented by the markedly 
improved arterial elastic properties and decrease of metalloproteases. 
In particular, the indices of distensibility and compliance increased, 
whereas arterial stiffness, a marker of increased cardiovascular risk 
in diabetic patients [41], was reduced by mesoglycan treatment. The 
vascular effects of mesoglycan seem reflect an action of mesoglycan 
per se on arterial wall remodeling. Other potential confounding 
factors which could act on vascular physiology, such as waist 
circumference and BMI, remained stable during treatment. In 
addition, the patients were not under physical training programs 
and did not change their physical activity during the trial. Moreover, 
other studies demonstrated an influence of mesoglycan on vascular 
function. For instance, it has been shown that three-month treatment 
with mesoglycan improves microvascular efficiency, as measured by 
cutaneous Laser Doppler flow metry, in women with chronic venous 
disorders [42] and, in another study, long-term treatment (18 months) 
with mesoglycan delayed the increase of the carotid intima-media 
thickness in subjects with high cardiovascular risk [43]. The current 
data provide direct information that mesoglycan is able to improve 
the whole spectrum of vascular indices in a group of patients who 
were free of vascular disease, but who already had established arterial 
dysfunction and a specific propensity to develop atherosclerotic 
disease. Of particular interest is the current observation that 
mesoglycan improved the metalloproteasis pattern in MetS patients. 
At the end of the trial, however, we observed both a significant 
reduction of MMP-9 and TIMP-1sieric levels and a modification of 
metalloproteinase’s activity MMP-9 92 kDa and MMP-9 240 kDa. 
Furthermore, the enzyme activity of the MMP-9 240 kDa resulted 
correlated with the improvement of the brachial elastic properties at 
the step ways multiple regression analysis. Metalloproteases pathways 
represent a precocious marker of subclinical atherosclerosis, which 
begins to impair at the same time of the worsening of the vascular 
reactivity. For these reasons, MMP-9 and TIMP-1 could play a 
significant role in the impairment of vascular physiology which 
characterizes the initial stages of MetS, acting as a pro-atherogenic 
factor which can cause endothelial dysfunction, inflammation, 
and, finally, concurs to the impairment of vascular remodeling 
[1,40,41,44-48]. The decrease of the sieric levels of metalloproteases, 
together with the improvement of the brachial vascular properties, 
could explain the anti atherosclerotic effects and the clinical benefits 
carried out by mesoglycan in some previous studies, even if the exact 
molecular mechanisms whereby mesoglycan exerts its vascular effects 
remains largely unknown. Therefore, our study was conducted on a 
small sample of patients, who were recruited from and studied in a 
single centre. Thus, the results of this small trial should be taken as 
preliminary information regarding the potential beneficial effects 
of mesoglycan on vascular physiology. Further studies, based on 
a larger sample of patients, are needed to confirm the current data. 
Therefore, the effects of mesoglycan on both vascular remodeling 
and metalloproteases pathways appear to be so marked to stimulate 
the design of large clinical trials aimed to test the potential efficacy of 
mesoglycan on hard clinical end-points.
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